+700.3%
MPC vs MRNA
+561.6%
+138.7%
-75.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.3% | -2.2% | +2.5% | +0.3% |
| 7D | +5.4% | +5.5% | 0.0% | +5.4% |
| 30D | +31.0% | +158.7% | -127.8% | +27.4% |
| 3M | +46.0% | +182.1% | -136.1% | +41.3% |
| 6M | +77.3% | +151.8% | -74.5% | +72.0% |
| YTD | +141.9% | +393.6% | -251.6% | +128.5% |
| 1Y | +120.9% | +499.5% | -378.5% | +106.7% |
| 3Y | +182.7% | +29.3% | +153.4% | +173.4% |
| 5Y | +646.4% | -65.1% | +711.5% | +639.4% |
| All | +700.3% | +561.6% | +138.7% | +561.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling